Steven Shallcross, Theriva Biologics CEO and CFO
Synthetic completes transformation with new name and cancer-killing virus focus
Just over a year ago, as Synthetic Biologics struggled to find cash for its C. difficile candidate, the team decided it was time for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
